BrissetJCKremerSHannounS, et al. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol. Epub ahead of print 31 January 2020. DOI: 10.1016/j.neurad.2020.01.083.
2.
McFarlandHFFrankJAAlbertPS, et al. Using gadolinium MRI using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol1992; 32: 758–766.
3.
RoviraAWattjesM. Gadolinium should always be used to assess disease activity in MS – No. Mult Scler2020; 26(7): 767–769.
4.
GranzieraCReichDS. Gadolinium should always be used to assess disease activity in MS – Yes. Mult Scler2020; 26(7): 765–766.
5.
KatzDTaubenbergerJKCannellaB, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol1993; 34: 661–669.
6.
AbsintaMVuoloLRaoA, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology2015; 85(1): 18–28.
7.
WoolenSAShankarPRGagnierJJ, et al. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. Epub ahead of print 9December2019. DOI: 10.1001/jamainternmed.2019.5284.
ZivadinovRBergslandNHagemeierJ, et al. Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology2019; 93(6): e611–e623.
10.
HaiderLNaismithRRoviraA. Use of gadolinium for MRI diagnostic or surveillance studies in patients with MS. Neurology2019; 93(6): 239–240.
11.
BowerDVRichterJKvon Tengg-KobligkH, et al. Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent. Invest Radiol2019; 54(8): 453–463.
12.
HeverhagenJTKnoppMV. Gadolinium retention in the brain: What do we need to consider for clinical use?Invest Radiol2019; 54(8): 466–467.
